Pfizer has made a new and improved bid to acquire AstraZeneca with an offer worth £69.3 billion pounds ($116.6 billion) or £55 a share – and says this is its best and final offer for the firm.

Pfizer: It is one of the largest and most successful ... Lilly’s stock has risen 25% in the past year. AstraZeneca: It boasts a diversified geographical footprint as well as a product portfolio ...

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

A small study published Monday found that the COVID-19 antiviral treatment Paxlovid may have use as a treatment for long ...

The latest health news highlights Trump considering an executive order to protect gas stoves, warnings for GSK's and Pfizer's ...

TD Cowen analyst Steve Scala maintained a Buy rating on AstraZeneca (AZN – Research Report) today. The company’s shares closed yesterday at ...

The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.